Form 4: Iovance Biotherapeutics Director Ryan Maynard Acquires Deferred Restricted Stock Units

Director Ryan Maynard acquired 49,303 deferred restricted stock units in Iovance Biotherapeutics, Inc. on June 11, 2024.

Summary

• Ryan Maynard, a director of Iovance Biotherapeutics, Inc., acquired 49,303 deferred restricted stock units (DRSUs) on June 11, 2024.
• These DRSUs represent a contingent right to receive one share of Iovance's common stock each.
• The DRSUs were granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
• The DRSUs will vest on the earlier of (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting, provided the Reporting Person continues to be providing service to the Issuer on the following dates.
• The issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction related to director compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of DRSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting and issuance of common stock are contingent upon continued service and other conditions as defined in the DRSU agreement.

Industry Context

This filing is a routine disclosure of a director's acquisition of company stock, which is common in the biopharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The acquisition of DRSUs by a director could positively influence shareholder sentiment.

Key Dates